Literature DB >> 7859616

Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control.

T Yamanouchi1, Y Akanuma.   

Abstract

We review the use of 1,5-anhydroglucitol (1,5 AG) in diagnosing and monitoring patients with diabetes. This six-carbon chain monosaccharide is one of the major polyols present in humans. Its concentration in serum is normally about 12 to 40 micrograms/ml. This substance is derived mainly from food, is well absorbed in the intestine, and is distributed to all organs and tissues. It is metabolically stable, being excreted in the urine when its level exceeds the renal threshold. It is reabsorbed in the renal tubules, and is competitively inhibited by glucosuria, which leads to a reduction in its level in serum. The correlation between this reduction and the amount of glucose present in urine is so close that 1,5 AG can be used as a sensitive, day-to-day, real-time marker of glycemic control. It provides useful information on current glycemic control and is superior to both HbA1c and fructosamine in detecting near-normoglycemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7859616     DOI: 10.1016/0168-8227(94)90259-3

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  31 in total

1.  Racial Differences in and Prognostic Value of Biomarkers of Hyperglycemia.

Authors:  Christina M Parrinello; A Richey Sharrett; Nisa M Maruthur; Richard M Bergenstal; Morgan E Grams; Josef Coresh; Elizabeth Selvin
Journal:  Diabetes Care       Date:  2015-12-17       Impact factor: 19.112

2.  The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring.

Authors:  Roy Beck; Michael Steffes; Dongyuan Xing; Katrina Ruedy; Nelly Mauras; Darrell M Wilson; Craig Kollman
Journal:  Pediatr Diabetes       Date:  2011-04-17       Impact factor: 4.866

3.  Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular Disease.

Authors:  Menglu Liang; John William McEvoy; Yuan Chen; A Richey Sharrett; Elizabeth Selvin
Journal:  Diabetes Care       Date:  2016-08-01       Impact factor: 19.112

4.  Glycated albumin but not HbA1c reflects glycaemic control in patients with neonatal diabetes mellitus.

Authors:  S Suzuki; M Koga; S Amamiya; A Nakao; K Wada; K Okuhara; S Hayano; A R Sarhat; H Takahashi; K Matsuo; Y Tanahashi; K Fujieda
Journal:  Diabetologia       Date:  2011-06-05       Impact factor: 10.122

Review 5.  Cardiovascular disease and 1,5-anhydro-d-glucitol.

Authors:  Nobutaka Ikeda; Yukio Hiroi
Journal:  Glob Health Med       Date:  2019-12-31

6.  Heritability analysis of nontraditional glycemic biomarkers in the Atherosclerosis Risk in Communities Study.

Authors:  Stephanie J Loomis; Adrienne Tin; Josef Coresh; Eric Boerwinkle; James S Pankow; Anna Köttgen; Elizabeth Selvin; Priya Duggal
Journal:  Genet Epidemiol       Date:  2019-06-19       Impact factor: 2.135

7.  Inverse association between 1,5-anhydroglucitol and neonatal diabetic complications.

Authors:  Enav Yefet; Shams Twafra; Neta Shwartz; Noura Hissin; Jamal Hasanein; Raul Colodner; Neetsa Mirsky; Zohar Nachum
Journal:  Endocrine       Date:  2019-08-21       Impact factor: 3.633

Review 8.  1,5-Anhydroglucitol in diabetes mellitus.

Authors:  Won Jun Kim; Cheol-Young Park
Journal:  Endocrine       Date:  2012-07-31       Impact factor: 3.633

Review 9.  Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management.

Authors:  Christina M Parrinello; Elizabeth Selvin
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

10.  Association of 1,5-anhydroglucitol with diabetes and microvascular conditions.

Authors:  Elizabeth Selvin; Andreea M Rawlings; Morgan Grams; Ronald Klein; Michael Steffes; Josef Coresh
Journal:  Clin Chem       Date:  2014-09-08       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.